Tejal A. Patel, MD
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Chief of Service, Medical Oncology MD Anderson Oncology Program at LBJ Hospital, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Postgraduate Training
| 2006-2009 | Research Fellowship, Hematology Oncology, Mayo Graduate School of Medicine, Jacksonville, FL |
| 2003-2003 | Clinical Residency, Internal Medicine, Mayo Graduate School of Medicine, Jacksonville, FL |
Board Certifications
| 2009 | American Board of Internal Medicine in Medical Oncology |
| 2009 | American Board of Internal Medicine Hematology |
Experience & Service
Academic Appointments
Assistant Professor, Weill Cornell Medical College, Houston, TX, 2012 - 2020
Assistant Professor, Houston Methodist Research, Houston, TX, 2012 - 2020
Instructor, Florida International University Herbert Wertheim College of Medicine, Miami, FL, 2010 - 2012
Instructor, Department of Hematology Oncology, Mayo Clinic, Jacksonville, FL, 2009 - 2010
Administrative Appointments/Responsibilities
Course Director, Houston Methodist Tumor Boards, Houston, TX, 2018 - 2020
Course Director, Houston Methodist Cancer Symposium, Houston, TX, 2017 - 2017
Program Director (authorized GSBS program), Department of Hematology Oncology Fellowship, Houston Methodist Research Institute, Houston, TX, 2016 - 2020
Honors & Awards
| 2022 | Vincente Valero LBJ Clinical Educator of the Year, MD Anderson Division of Cancer Medicine, Hematology Oncology Fellowship |
| 2021 | Vincente Valero LBJ Clinical Educator of the Year, MD Anderson Division of Cancer Medicine, Hematology Oncology Fellowship |
| 2020 | Vincente Valero LBJ Clinical Educator of the Year, MD Anderson Division of Cancer Medicine, Hematology Oncology Fellowship |
Selected Publications
Peer-Reviewed Articles
- Sun K, Xu Y, Zhang L, Niravath P, Darcourt J, Patel T, Teh BS, Farach AM, Guerrero C, Mathur S, Sultenfuss MA, Gupta N, Schwartz MR, Haley SL, Nair S, Li X, Nguyen TTA, Butner JD, Ensor J, Mejia JA, Mei Z, Butler EB, Chen SH, Bernicker EH, Chang JC. A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 28(20):4392-4401, 2022. PMID: 35877117.
- Puri A, Mylavarapu C, Xu J, Patel TA, S Teh B, Tremont-Lukats I, Chang JC, Niravath P. Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases. Breast Cancer Res Treat 193(3):613-623, 2022. e-Pub 2022. PMID: 35460498.
- Chung AW, Anand K, Anselme AC, Chan AA, Gupta N, Venta LA, Schwartz MR, Qian W, Xu Y, Zhang L, Kuhn J, Patel T, Rodriguez AA, Belcheva A, Darcourt J, Ensor J, Bernicker E, Pan PY, Chen SH, Lee DJ, Niravath PA, Chang JC. A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Sci Transl Med 13(624):eabj5070, 2021. e-Pub 2021. PMID: 34910551.
- Tennison JM, Fricke BC, Fu JB, Patel TA, Chen M, Bruera E. Medical Complications and Prognostic Factors for Medically Unstable Conditions During Acute Inpatient Cancer Rehabilitation. JCO Oncol Pract 17(10):e1502-e1511, 2021. e-Pub 2021. PMID: 33683918.
- Koca E, Niravath PA, Ensor J, Patel TA, Li X, Hemati P, Wong H, Qian W, Boone T, Zhao J, Ramshesh PV, Cohen AL, Murthy A, Nair S, Darcourt JG, Belcheva A, Kaklamani VG, Chang JCN. ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat 188(2):433-439, 2021. e-Pub 2021. PMID: 33860388.
- Burns E, Koca E, Xu J, McLean E, Lee R, Patel T, Chang J, Niravath P. Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy. Oncologist 26(6):e936-e942, 2021. e-Pub 2021. PMID: 33594769.
- Anand K, Niravath P, Patel T, Ensor J, Rodriguez A, Boone T, Wong ST, Chang JC. A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer. Clin Breast Cancer 21(3):199-204, 2021. e-Pub 2020. PMID: 34159901.
- Anand K, Patel T, Niravath P, Rodriguez A, Darcourt J, Belcheva A, Boone T, Ensor J, Chang J. Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy. Sci Rep 11(1):82, 2021. e-Pub 2021. PMID: 33420229.
- Jaeckle KA, Dixon JG, Anderson SK, Moreno-Aspitia A, Colon-Otero G, Hebenstreit K, Patel TA, Reddy SL, Perez EA. Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases. Cancer Med 9(21):7935-7942, 2020. e-Pub 2020. PMID: 32885617.
- Puri A, Reddy TP, Patel TA, Chang JC. Metastatic Triple-Negative Breast Cancer: Established and emerging treatments. Breast J 26(9):1793-1796, 2020. e-Pub 2020. PMID: 32578306.
- Lewis GD, Xing Y, Haque W, Patel T, Schwartz MR, Chen AC, Farach A, Hatch SS, Butler EB, Chang JC, Teh BS. The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast. Breast J 25(6):1171-1176, 2019. e-Pub 2019. PMID: 31321854.
- Lewis GD, Xing Y, Haque W, Patel T, Schwartz M, Chen A, Farach A, Hatch SS, Butler EB, Chang J, Teh BS. Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database. Cancer Commun (Lond) 39(1):60, 2019. e-Pub 2019. PMID: 31639071.
- Patel TA, Ensor JE, Creamer SL, Boone T, Rodriguez AA, Niravath PA, Darcourt JG, Meisel JL, Li X, Zhao J, Kuhn JG, Rosato RR, Qian W, Belcheva A, Schwartz MR, Kaklamani VG, Chang JC. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study). Breast Cancer Res 21(1):100, 2019. e-Pub 2019. PMID: 31477168.
- Messer JA, Ekinci E, Patel TA, Teh BS. Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: A case report. Rep Pract Oncol Radiother 24(3):276-280, 2019. e-Pub 2019. PMID: 30948930.
- He T, Puppala M, Ezeana CF, Huang YS, Chou PH, Yu X, Chen S, Wang L, Yin Z, Danforth RL, Ensor J, Chang J, Patel T, Wong STC. A Deep Learning-Based Decision Support Tool for Precision Risk Assessment of Breast Cancer. JCO Clin Cancer Inform 3:1-12, 2019. PMID: 31141423.
- Stubbins R, He T, Yu X, Puppala M, Ezeana CF, Chen S, Valdivia Y Alvarado M, Ensor J, Rodriguez A, Niravath P, Chang J, Wong STC, Patel T. A Behavior-Modification, Clinical-Grade Mobile Application to Improve Breast Cancer Survivors' Accountability and Health Outcomes. JCO Clin Cancer Inform 2:1-11, 2018. PMID: 30652617.
- Patel TA, Puppala M, Ogunti RO, Ensor JE, He T, Shewale JB, Ankerst DP, Kaklamani VG, Rodriguez AA, Wong ST, Chang JC. Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods. Cancer 123(1):114-121, 2017. e-Pub 2016. PMID: 27571243.
- Liang DH, Ensor JE, Liu ZB, Patel A, Patel TA, Chang JC, Rodriguez AA. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients. Breast Cancer Res Treat 155(1):139-49, 2016. e-Pub 2015. PMID: 26667234.
- Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G. Erratum: Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res 16(6):468, 2014. e-Pub 2014. PMID: 25927825.
- Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G. Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res 16(4):419, 2014. e-Pub 2014. PMID: 25928889.
- Moreno-Aspitia A, Dueck AC, Ghanem-Canete I, Patel T et al. RCO639: A phase II study of Paclitaxel, Trastuzumab and Lapatinib as adjuvant therapy for early stage HER2 positive breast cancer. Breast Cancer Res Treat, 2013.
- Perez EA, Patel T, Moreno-Aspitia A.. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat, 2013.
- Patel TA, Colon-Otero G, Hume CB, Copland JA 3rd, Perez EA.. Breast Cancer in Latinas: Gene Expression, Differential Response to Treatments, and Differential Toxicities in Latinas Compared with Other Population Groups. The Oncologist, 2010.
- Saurel CA, Patel TA, Perez, EA.. Changes to Adjuvant Systemic Therapy in Breast Cancer. A Decade in Review. Clinical Breast Cancer, 2010.
- Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC.. N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. North Central Cancer Treatment Group, 2009.
Book Chapters
- David Hui, Alexander A. Leung, Christopher Ma. Oncology. In: Approach to Internal Medicine 5ed Oncology Section, 2022.